Physician profile
Drew P Ronnermann
NPI 1235101999
$5,068.92
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $663 · 2021: $1,442 · 2022: $1,748 · 2023: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.84 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,098.22 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $530.28 | 2019-2022 | |
| Janssen Biotech, INC. | $343.32 | 2019-2022 | |
| Gilead Sciences, INC. | $235.27 | 2019-2022 | |
| Celgene Corporation | $208.39 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $140.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $134.09 | 2019-2022 | |
| Braintree Laboratories, INC. | $131.78 | 2021-2022 | |
| Shionogi INC | $108.57 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $99.03 | 2020-2022 | |
| Pfizer INC. | $78.53 | 2019-2022 | |
| Daiichi Sankyo INC. | $75.42 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $69.90 | 2020-2022 | |
| Qol Medical, LLC | $66.83 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $55.69 | 2019 | |
| Genzyme Corporation | $46.53 | 2022 | |
| Ferring Pharmaceuticals INC. | $43.46 | 2019-2021 | |
| Ucb, INC. | $42.14 | 2019-2021 | |
| Allergan, INC. | $38.28 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $37.54 | 2022-2023 | Givlaari |
| Concordia Pharmaceuticals INC. | $28.97 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.88 | 2019 | |
| Boston Scientific Corporation | $23.69 | 2019 | |
| Advanced Respiratory, INC | $23.51 | 2020 | |
| Nevro Corp. | $22.83 | 2019 | |
| Shire North American Group INC | $22.77 | 2019 | |
| Romark Laboratories, Lc | $22.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.78 | 2019 | |
| Alfasigma USA, INC. | $15.90 | 2022 | |
| Philips North America LLC | $14.21 | 2019 | |
| Medtronic, INC. | $12.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2019 | |
| Amgen INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Ronnermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.